Screening for prostate cancer - More questions than answers

Acta Oncologica

Volumn 37, Issue 6, 1998, Pages 515-532

  Rietbergen, John B W ^a   Schröder, Fritz H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

AGE DISTRIBUTION; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER STAGING; DISEASE COURSE; EARLY DIAGNOSIS; GEOGRAPHY; HIGH RISK POPULATION; HUMAN; INCIDENCE; MALE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

EID: 0031733675     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/028418698430214     Document Type: Review

References (179)

1. Schröder FH, Boyle P. Screening for prostate cancer - necessity or nonsense? Eur J Cancer 1993; 29A: 656-61.
2. Chodak GW. Questioning the value of screening for prostate cancer in asymptomatic men (editorial). Urology 1993; 42: 116-8.
3. Collins MM, Barry MJ. Controversies in prostate cancer screening. Analogies to the early lung cancer screening debate. JAMA 1996; 276: 1976-9.
4. American Urological Association: Position statement. Annual meeting, May 1993.
5. American Cancer Society. Position statement. Annual meeting, May 1993.
6. Adami HO, Baron JA, Rothman KJ. Ethics of a prostate cancer screening trial. Lancet 1994; 343: 958-60.
7. Visser O, Coebergh JWW, Schouten LJ. Incidence of cancer in the Netherlands: The fourth report of the Netherlands cancer registry. Utrecht: SIG Health Care Information, 1995.
8. Lu-Yao GL, Greenberg ER. Changes in prostate cancer incidence and treatment in the USA. Lancet 1994; 343: 251-4.
9. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995; 273: 548-52.
10. Møller Jensen O, Estève J, Møller H, Renard H. Cancer in the European Community and its member states. Eur J Cancer 1990; 26: 1167-256.
11. Boyle P, Maisonneuve P, Napalkov P. Geographical and temporal patterns of incidence and mortality from prostate cancer. Urology 1995; 46 (Suppl 3A): 47-55.
12. Seidman H, Mushinski MH, Gelb SK, Silverberg E. Probabilities of eventually developing or dying of cancer - United States, 1985. CA Cancer J Clin 1985; 35: 36-56.
13. Wilson JMG, Jungner G. Principles and practice of screening for disease. Geneva: WHO, 1968: Public Health Paper No. 34.
14. Franks LM. Latent carcinoma of the prostate. J Pathol Bacteriol 1954; 68: 603-16.
15. Gaynor EP. Zur frage des prostatakrebs. Virchow's Arch Path Anat 1938; 301: 602-52.
16. Hølund B. Latent prostate cancer in a consecutive autopsy series. Scand J Urol Nephrol 1980; 14: 29-35.
17. Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol 1993; 150: 379-85.
18. Montie JE, Wood DP, Pontes JE, Boyett JM, Levin HS. Adenocarcinoma of the prostate in cystoprostatectomy specimens removed for bladder cancer. Cancer 1989; 63: 381-5.
19. Kabalin JN, McNeal JE, Price HM, Freiha FS, Stamey TA@. Unsuspected adenocarcinoma of the prostate in patients undergoing cystoprostatectomy for other causes: incidence, histology and morphometric observations. J Urol 1989;141: 1091-4; discussion 1093-4.
20. Ohori M, Wheeler TM, Dunn JK, Stamey TA, Scardino PT. The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol 1994; 152: 1714-20.
21. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993; 71 (Suppl 3): 933-8.
22. Surveillance, Epidemiology and end results. Incidence and mortality data: 1973-1977. Bethesda (MD): National Cancer Institute Monograph 57; 1981; publication No (NIH) 81-2330.
23. Murphy GP, Natarajan N, Pontes JE, et al. The national survey of prostate cancer in the United States by the American College of Surgeons. J Urol 1982; 127: 928-34.
24. Visser O, Horenblas S. Incidentie en behandeling van prostaatcarcinoom in de regio van het integraal kankercentrum Amsterdam, 1989-1994. Ned Tijdschr Geneeskd 1996; 140: 2627-31.
25. Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321: 419-24.
26. Bumpus HC. Carcinoma of the prostate. A clinical study of one thousand cases. Surg Gynecol Obstet 1926; 46: 150-5.
27. Nesbit RM, Plumb RT. Prostatic carcinoma. A follow-up on 795 patients treated prior to the endocrine era and a comparison of survival-rates between these and patients treated by endocrine therapy. Surgery 1946; 20: 263-72.
28. Handley R, Carr TW, Travis D, Powell PH, Hall RR. Deferred treatment for prostate cancer. Br J Urol 1988; 62: 249-53.
29. Johansson JE, Adami HO, Andersson SO, Bergstrom R, Holmberg L, Krusemo UB. High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA 1992; 267: 2191-6.
30. Johansson JE. Expectant management of early stage pro-static cancer: Swedish experience. J Urol 1994; 152: 1753-6.
31. Johansson JE, Holmberg L, Johansson S, Bergstrom R, Adami HO. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA 1997; 277: 467-71.
32. Chodak GW, Thisted RA, Gerber GS, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994; 330: 242-8.
33. Aus G, Pileblad E, Hugosson J. Impact of competing mortality on the cancer-related mortality in localized prostate cancer. Urology 1995; 46: 672-5.
34. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. Long-term survival among men with conservatively treated localized prostate cancer. JAMA 1995; 274: 626-31.
35. Schmid HP, McNeal JE, Stamey TA. Clinical observations on the doubling time of prostate cancer. Eur Urol 1993; 23 (Suppl 2): 60-3.
36. Schmid HP, McNeal JE, Stamey TA. Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer 1993; 71: 2031-40.
37. Ohori M, Scardino PT. Early detection of prostate cancer: the nature of cancers detected with current diagnostic tests. Semin Oncol 1994; 21: 522-6.
38. Scardino PT, Weaver R, Hudson MA. Early detection of prostate cancer. Hum Pathol 1992; 23: 211-22.
39. McNeal JE, Bostwick DG, Kindrachuk RA, Redwine EA, Freiha FS, Stamey TA. Patterns of progression in prostate cancer. Lancet 1986; 1: 60-3.
40. McNeal JE, Villers AA, Redwine EA, Freiha FS, Stamey TA. Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate. Cancer 1990; 66: 1225-33.
41. Breslow N, Chan CW, Dhom G, et al. Latent carcinoma of the prostate at autopsy in seven areas. Int J Cancer 1977; 20: 680-8.
42. Haenszel W, Kurihara M. Mortality from cancer and other diseases among Japanese in the United States. J Natl Cancer Inst 1968; 40: 43-68.
43. Mills PK, Beeson WL, Phillips RL, Fraser GE. Cohort study of diet, lifestyle, and prostate cancer in Adventist men. Cancer 1989; 64 (3): 598-604.
44. Clinton SK, Emenhiser C, Schwartz SJ, et al. Cis - trans lycopene isomers, carotenoids, and retinol in the human prostate. Cancer Epidemiol Biomarkers Prev 1996; 5: 823-33.
45. Giovannucci E, Ascherio A, Rimm EB, Stampfer MJ, Colditz GA, Willett WC. Intake of carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst 1995; 87: 1767-76.
46. Rao GN. Influence of diet on tumors of hormonal tissues. Prog Clin Biol Res 1996; 394: 41-56.
47. Gann PH, Hennekens CH, Sacks FM, et al. Prospective study of plasma fatty acids and risk of prostate cancer. Journal of the National Cancer Institute 1994; 86: 281-6.
48. Wang Y, Corr JG, Thaler HT, Tao Y, Fair WR, Heston WD. Decreased growth of established human prostate LN-CaP tumors in nude mice fed a low-fat diet. J Natl Cancer Inst 1995; 87: 1456-62.
49. Bastacky SI, Wojno KJ, Walsh PC, Carmichael MJ, Epstein JI. Pathological features of hereditary prostate cancer. J Urol 1995; 153: 987-92.
50. Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC. Family history and the risk of prostate cancer. Prostate 1990; 17: 337-47.
51. Tsukamoto S, Akaza H, Onozawa M, Imade S, Tsukuba, Shirai T. Chemoprevention of rat prostate carcinogenesis by use of finasteride or casodex: A study of dose finding (Ab-stract 886). J Urol 1997; 157: 227.
52. Pienta KJ, Esper PS, Zwas F, Krzeminski R, Flaherty LE. Phase II chemoprevention trial of oral fenretinide in patients at risk for adenocarcinoma of the prostate. Am J Clin Oncol 1997; 20: 36-9.
53. Brawley OW, Ford LG, Thompson I, Perlman JA, Kramer BS. 5-Alpha-reductase inhibition and prostate cancer prevention. Cancer Epidemiol Biomarkers Prev 1994; 3: 177-82.
54. Brawley OW, Thompson IM. Chemoprevention of prostate cancer. Urology 1994; 43: 594-9.
55. Mettlin C, Natarajan N, Murphy GP. Recent patterns of care of prostate cancer patients in the United States: results from the surveys of the American College of Surgeons Commission on Cancer. Int Adv Surg Oncol 1982; 5: 277-321.
56. Rosen MA, Goldstone L, Lapin S, Wheeler T, Scardino PT. Frequency and location of extracapsular extension and positive surgical margins in radical prostatectomy specimens. J Urol 1992; 148: 331-7.
57. Stamey TA, Ferrari MK, Schmid HP. The value of serial prostate specific antigen determinations 5 years after radiotherapy: steeply increasing values characterize 80% of patients. J Urol 1993; 150: 1856-9.
58. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 1156-61.
59. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993; 270: 948-54.
60. Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6630 men. J Urol 1994; 151: 1283-90.
61. Mettlin C, Murphy GP, Lee F, et al. Characteristics of prostate cancer detected in the American Cancer Society-National Prostate Cancer Detection Project. J Urol 1994; 152: 1737-40.
62. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 1995; 273: 289-94.
63. Watanabe H, Kaiho H, Tanaka M, Terasawa Y. Diagnostic application of ultrasonotomography to the prostate. Invest Urol 1971; 8: 548-59.
64. Watanabe H, Igari D, Tanahashi Y, Harada K, Saitoh M. Transrectal ultrasonotomography of the prostate. J Urol 1975; 114: 734-9.
65. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol 1979; 17: 159-63.
66. Lilja H, Laurell CB. Liquefaction of coagulated human semen. Scand J Clin Invest 1984; 44: 447-52.
67. Lepor H, Wang B, Shapiro E. Relationship between prostatic epithelial volume and serum prostate-specific antigen levels. Urology 1994; 44: 199-205.
68. Elgamal AA, Ectors NL, Sunardhi-Widyaputra S, Van Poppel HP, Van Damme BJ, Baert LV. Detection of prostate specific antigen in pancreas and salivary glands: a potential impact on prostate cancer overestimation. J Urol 1996; 156: 464-8.
69. Graves HCB. Nonprostatic sources of prostate-specific antigen: a steroid hormone dependent phenomenon? Clin Chem 1995; 41: 7-9.
70. Agha AH, Schechter E, Roy JB, Culkin DJ. Prostate specific antigen is metabolized in the liver. J Urol 1996; 155: 1332-5.
71. Aus G, Bergdahl S, Prosing R, Lodding P, Pileblad E, Hugosson J. Reference range of prostate-specific antigen after trans-urethral resection of the prostate. Urology 1996; 47 (4): 529-31.
72. Yuan JJJ, Coplen DE, Petros JA, et al. Effects of rectal examination, prostatic massage, ultrasonography and needle biopsy on serum prostate specific antigen levels. J Urol 1992; 147: 810-4.
73. Breul J, Binder K, Block T, Hartung R. Effect of digital rectal examination on serum concentration of prostate-specific antigen. Eur Urol 1992; 21: 195-9.
74. Tchetgen MB, Song JT, Strawderman M, Jacobsen SJ, Oesterling JE. Ejaculation increases the serum prostate-specific antigen concentration. Urology 1996; 47: 511-6.
75. Herschman JD, Smith DS, Catalona WJ. Effect of ejaculation on serum total and free prostate-specific antigen concentrations. Urology 1997; 50: 239-43.
76. Kirkali Z, Kirkali G, Esen A. Effect of ejaculation on prostate-specific antigen levels in normal men. Eur Urol 1995; 27: 292-4.
77. Netto NR Jr, Apuzzo F, de Andrade E, Srulzon GB, Cortado PL, Lima ML. The effects of ejaculation on serum prostate specific antigen. J Urol 1996; 155: 1329-31.
78. Simak R, Madersbacher S, Zhang ZF, Maier U. The impact of ejaculation on serum prostate specific antigen. J Urol 1993; 150: 895-7.
79. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317: 909-16.
80. Stamey TA, Kabalin JN, McNeal JE, et al. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. II. Radical prostatectomy treated patients. J Urol 1989; 141: 1076-83.
81. Parkes C, Wald NJ, Murphy P, et al. Prospective observational study to assess value of prostate specific antigen as screening test for prostate cancer. Br Med J 1995; 311: 1340-3.
82. Whittemore AS, Lele C, Friedman GD, Stamey T, Vogelman JH, Orentreich N. Prostate-specific antigen as predictor of prostate cancer in black men and white men. J Natl Cancer Inst 1995; 87: 354-60.
83. Stenman UH, Hakama M, Knekt P, Aromaa A, Teppo L, Leinonen J. Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer. Lancet 1994; 344: 1594-8.
84. Catalona WJ, Hudson MA, Scardino PT, et al. Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J Urol 1994; 152: 2037-42.
85. Labrie F, Dupont A, Suburu R, et al. Serum prostate specific antigen as pre-screening test for prostate cancer. J Urol 1992; 147: 846-51.
86. Babaian RJ, Mettlin C, Kane R, et al. The relationship of prostate-specific antigen to digital rectal examination and transrectal ultrasonography. Findings of the American Cancer Society National Prostate Cancer Detection Project. Cancer 1992; 69: 1195-200.
87. Mettlin C, Lee F, Drago J, Murphy GP. The American Cancer Society National Prostate Cancer Detection Project. Findings on the detection of early prostate cancer in 2425 men. Cancer 1991; 67: 2949-58.
88. Mettlin C, Murphy GP, Babaian RJ, et al. The results of a five-year early prostate cancer detection intervention. Investigators of the American Cancer Society National Prostate Cancer Detection Project. Cancer 1996; 77: 150-9.
89. Gustafsson O, Norming U, Almgard LE, et al. Diagnostic methods in the detection of prostate cancer: a study of a randomly selected population of 2400 men. J Urol 1992; 148: 1827-31.
90. Crawford ED, DeAntoni EP, Etzioni R, Schaefer VC, Olson RM, Ross CA. Serum prostate-specific antigen and digital rectal examination for early detection of prostate cancer in a national community-based program. The Prostate Cancer Education Council. Urology 1996; 47: 863-9.
91. Cooner WH, Mosley BR, Rutherford CL, Jr, et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol 1990;143: 1146-2; discussion 1152-4.
92. Chodak GW, Keller P, Schoenberg HW. Assessment of screening for prostate cancer using the digital rectal examination. J Urol 1989; 141: 1136-8.
93. Pedersen KV, Carlsson P, Varenhorst E, Lofman O, Berglund K Screening for carcinoma of the prostate by digital rectal examination in a randomly selected population. Br Med J 1991; 300: 1041-4.
94. Smith DS, Catalona WJ. Interexaminer variability of digital rectal examination in detecting prostate cancer. Urology 1995; 45: 70-4.
95. Lee F, Gray JM, McLeary RD, et al. Transrectal ultrasound in the diagnosis of prostate cancer: location, echogenicity, histopathology, and staging. Prostate 1985; 7: 117-29.
96. Terris MK, Freiha FS, McNeal JE, Stamey TA. Efficacy of transrectal ultrasound for identification of clinically undetected prostate cancer. J Urol 1991; 146: 78-83; discussion 83-84.
97. Lee F, Torp-Pedersen S, Littrup PJ, et al. Hypoechoic lesions of the prostate: clinical relevance of tumor size, digital rectal examination and prostate specific antigen. Radiology 1989; 170: 29-32.
98. Ellis WJ, Chetner MP, Preston SD, Brawer MK. Diagnosis of prostatic carcinoma: the yield of serum prostate specific antigen, digital rectal examination and transrectal ultrasonography. J Urol 1994; 152: 1520-5.
99. Schröder FH, Hermanek P, Denis L, Fair WR, Gospodarowicz MK, Pavone-Macaluso M. The TNM classification of prostate cancer. Prostate 1992; 4: 129-38.
100. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271: 368-74.
101. Brendler CB. Characteristics of prostate cancer found with early detection regimens. Urology 1995; 46 (Suppl 3A): 71-6.
102. Matthews GJ, Fracchia JA. PSA-detected prostate cancer: contrasts with palpable disease. J Surg Oncol 1995; 59: 28-30.
103. Oesterling JE, Suman VJ, Zincke H, Bostwick DG. PSA-detected (clinical stage T1c or BO) prostate cancer. Pathologically significant tumors. Urol Clin North Am 1993; 20: 687-93.
104. Babaian RJ, Fritsche HA, Evans RB. Prostate-specific antigen and prostate gland volume: correlation and clinical application. J Clin Lab Anal 1990; 4: 135-7.
105. Babaian RJ, Miyashita H, Evans RB, Ramirez EI. The distribution of prostate specific antigen in men without clinical or pathological evidence of prostate cancer: relationship to gland volume and age. J Urol 1992; 147: 837-40.
106. Benson MC, Whang IS, Olsson CA, McMahon DJ, Cooner WH. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 1992; 147: 817-21.
107. Benson MC, Whang IS, Pantuck A, et al. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 1992; 147: 815-6.
108. Bazinet M, Meshref AW, Trudel C, et al. Prospective evaluation of prostate specific antigen density and systematic biopsies for early detection of prostatic carcinoma. Urology 1994; 43: 44-52.
109. Littrup PJ, Kane RA, Mettlin CJ, et al. Cost-effective prostate cancer detection. Reduction of low-yield biopsies. Investigators of the American Cancer Society National Prostate Cancer Detection Project. Cancer 1994; 74: 3146-58.
110. Catalona WJ, Richie JP, deKernion JB, et al. Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves. J Urol 1994; 152: 2031-6.
111. Cookson MS, Floyd MK, Ball TP, Jr, Miller EK, Sarosdy MF. The lack of predictive value of prostate specific antigen density in the detection of prostate cancer in patients with normal rectal examinations and intermediate prostate specific antigen levels. J Urol 1995; 154: 1070-3.
112. Bare R, Hart L, McCullough DL. Correlation of prostate-specific antigen and prostate-specific antigen density with outcome of prostate biopsy. Urology 1994; 43: 191-6.
113. Ohori M, Dunn JK, Scardino PT. Is prostate-specific antigen density more useful than prostate-specific antigen levels in the diagnosis of prostate cancer? Urology 1995; 46: 666-71.
114. Brawer MK, Aramburu EA, Chen GL, Preston SD, Ellis WJ. The inability of prostate specific antigen index to enhance the predictive value of prostate specific antigen in the diagnosis of prostatic carcinoma. J Urol 1993; 150: 369-73.
115. Bosch JL, Hop WC, Bangma CH, Kirkels WJ, Schröder FH. Prostate specific antigen in a community-based sample of men without prostate cancer: correlations with prostate volume, age, body mass index, and symptoms of prostatism. Prostate 1995; 27: 241-9.
116. Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993; 270: 860-4.
117. Oesterling JE, Jacobsen SJ, Cooner WH. The use of age-specific reference ranges for serum prostate specific antigen in men 60 years old or older. J Urol 1995; 153: 1160-3.
118. Partin AW, Criley SR, Subong EN, Zincke H, Walsh PC, Oesterling JE. Standard versus age-specific prostate specific antigen reference ranges among men with clinically localized prostate cancer: A pathological analysis. J Urol 1996; 155: 1336-9.
119. el-Galley RES, Petros FRCS, Sanders WH, et al. Normal range prostate specific antigen versus age specific prostate specific antigen in screening prostate adenocarcinoma. Urology 1995; 46: 200-4.
120. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostate specific antigen and a1-antichimotrypsin is the major form of prostate specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991; 51: 222-6.
121. Catalona WJ, Smith DS, Wolfert RL, et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 1995; 274: 1214-20.
122. Van Cangh PJ, De Nayer P, Sauvage P, et al. Free to total prostate-specific antigen (PSA) ratio is superior to total-PSA in differentiating benign prostate hypertrophy from prostate cancer. Prostate 1996; 7: 30-4.
123. Bangma CH, Rietbergen JB, Kranse R, Blijenberg BG, Petterson K, Schröder FH. The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population. J Urol 1997; 157: 2191-6.
124. Hugosson J, Aus G, Bergdahl S, et al. Results of a population bases randomized study of PSA screening for prostate cancer (Abstract 459). J Urol 1997; 157: 118.
125. Bangma CH, Rietbergen JBW, Schröder FH. Prostate specific antigen as a screening test: The Netherlands experience. Urol Clin North Am 1997; 24: 307-14.
126. Roehrborn CG, Gregory A, McConnell JD, Sagalowsky AI, Wians FH, Jr. Comparison of three assays for total serum prostate-specific antigen and percentage of free prostate-specific antigen in predicting prostate histology. Urology 1996; 48 (Suppl 6A): 23-32.
127. Eposti PL, Elman A, Norlén H. Complications of transrectal aspiration biopsy of the prostate. Scand J Urol Nephrol 1975; 9: 208-13.
128. Edson RS, Scoy van RE, Leary FJ. Gram negative bacteremia after transrectal needle biopsy of the prostate. Mayo Clin Proc 1980; 55: 489-91.
129. Davison P, Malament M. Urinary contamination as a result of transrectal biopsy of the prostate. J Urol 1971; 105: 545-6.
130. Norberg M. Transrectal ultrasound and core biopsies for the diagnosis of prostate cancer. Acta Radiol 1994; 393: 1-21.
131. Terris MK, McNeal JE, Stamey TA. Detection of clinically significant prostate cancer by transrectal ultrasound-guided systematic biopsies. J Urol 1992; 148: 829-32.
132. Daneshgari F, Taylor GD, Miller GJ, Crawford ED. Computer simulation of the probability of detecting low volume carcinoma of the prostate with six random systematic core biopsies. Urology 1995; 45: 604-9.
133. Roehrborn CG, Pickens GJ, Sanders JS. Diagnostic yield of repeated transrectal ultrasound-guided biopsies stratified by specific histopathologic diagnoses and prostate specific antigen levels. Urology 1996; 47: 347-52.
134. Karakiewicz PI, Bazinet M, Aprikian AG, et al. Outcome of sextant biopsy according to gland volume. Urology 1997; 49: 55-9.
135. Uzzo RG, Wei JT, Waldbaum RS, Perlmutter AP, Byrne JC, Vaughan ED. The influence of prostate size on cancer detection. Urology 1995; 46: 831-6.
136. Eskew LA, Bare RL, McCullough DL. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol 1997; 157: 199-202; discussion 202-3.
137. Goldstein NS, Begin LR, Grody WW, Novak JM, Qian J, Bostwick DG. Minimal or no cancer in radical prostatectomy specimens. Report of 13 cases of the 'vanishing cancer phenomenon'. Am J Surg Pathol 1995; 19: 1002-9.
138. Ravery V, Szabo J, Toublanc M, et al. A single positive prostate biopsy in six does not predict a low-volume prostate tumour. Br J Urol 1996; 77: 724-8.
139. Cupp MR, Bostwick DG, Myers RP, Oesterling JE. The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis. J Urol 1995; 153: 1543-8.
140. Epstein JI, Walsh PC, Brendler CB. Radical prostatectomy for impalpable prostate cancer: the Johns Hopkins experience with tumors found on transurethral resection (stages T1A and T1B) and on needle biopsy (stage T1C). J Urol 1994; 152: 1721-9.
141. Bostwick DG. Gleason grading of prostatic needle biopsies. Correlation with grade in 316 matched prostatectomies. Amer J Surg Path 1994; 18: 796-803.
142. Johnstone PA, Riffenburgh R, Saunders EL, Willison FW. Grading inaccuracies in diagnostic biopsies revealing prostatic adenocarcinoma: implications for definitive radiation therapy. Int J Radiat Oncol Biol Phys 1995; 32: 479-82.
143. Epstein JI, Steinberg GD. The significance of low-grade prostate cancer on needle biopsy. A radical prostatectomy study of tumor grade, volume, and stage of the biopsied and multifocal tumor. Cancer 1990; 66: 1927-32.
144. Kojima M, Troncoso P, Babaian RJ. Use of prostate-specific antigen and tumor volume in predicting needle biopsy grading error. Urology 1995; 45: 807-12.
145. Bostwick DG, Qian J, Bergstralh E, et al. Prediction of capsular perforation and seminal vesicle invasion in prostate cancer. J Urol 1996; 155: 1361-7.
146. Amico AV, Chang H, Holupka E, et al. Calculated prostate cancer volume: the optimal predictor of actual cancer volume and pathologic stage. Urology 1997; 49: 385-91.
147. Partin AW, Yoo J, Carter HB, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993; 150: 110-4.
148. Partin AW, Kattan MW, Subong ENP, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. JAMA 1997; 277: 1445-51.
149. Labrie F, Dupont A, Suburu R, et al. Optimized strategy for detection of early stage, curable prostate cancer: role of prescreening with prostate-specific antigen. Clin Invest Med 1993; 16: 425-39.
150. Smith DS, Catalona WJ, Herschman JD. Longitudinal screening for prostate cancer with prostate-specific antigen. JAMA 1996; 276: 1309-15.
151. Carter HB, Epstein JI, Chan DW, Fozard JL, Pearson JD. Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer. JAMA 1997; 277: 1456-60.
152. Graversen PH, Nielsen KT, Gasser TC, DKC, Madsen PO. Radical prostatectomy versus expectant primary treatment in stages I and II prostatic cancer. Urology 1990; 36: 493-498.
153. Paulson DF, Lin GH, Hinshaw W, Stephani S. Radical surgery versus radiotherapy for adenocarcinoma of the prostate. J Urol 1982; 128: 502-4.
154. Wilt TJ, Brawer MK The Prostate Cancer Intervention Versus Observation Trial: a randomized trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer. J Urol 1994; 152 (5 Pt 2): 1910-4.
155. Norlen BJ. Swedish randomized trial of radical prostatectomy versus watchful waiting. Can J Oncol 1994; 4: 38-40.
156. Austenfeld MS, Thompson IM, Jr, Middleton RG. Metaanalysis of the literature: guideline development for prostate cancer treatment. American Urological Association Prostate Cancer Guideline Panel. J Urol 1994; 152: 1866-9.
157. Middleton RG, Thompson IM, Austenfeld MS, et al. Prostate Cancer Clinical Guidelines Panel summary report on the management of clinically localized prostate cancer. The American Urological Association. J Urol 1995; 154: 2144-8.
158. Hanks GE, Asbell S, Krall JM, et al. Outcome for lymph node dissection negative T-1b, T-2 (A-2,B) prostate cancer treated with external beam radiation therapy in RTOG 77-06. Int J Radiat Oncol Biol Phys 1991; 21: 1099-103.
159. Powell CR, Huisman TK, Riffenburgh RH, Saunders EL, Bethel KJ, Johnstone PAS. Outcome for surgically staged localized prostate cancer treated with external beam radiation therapy. J Urol 1997; 157: 1754-9.
160. Gerber GS, Thisted RA, Scardino PT, et al. Results of radical prostatectomy in men with clinically localized prostate cancer. JAMA 1996; 276: 615-9.
161. Lu-Yao GL, Yao SL. Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet 1997; 349: 906-10.
162. Partin AW, Lee BR, Carmichael M, Walsh PC, Epstein JI. Radical prostatectomy for high grade disease: a re-evaluation 1994. J Urol 1994; 151: 1583-6.
163. Ohori M, Goad JR, Wheeler TM, Eastham JA, Thompson TC, Scardino PT. Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol 1994; 152: 1843-9.
164. Chodak GW, Thisted RA. Comparison of cancer specific survival (CSS) following radical prostatectomy (RP) or watchful waiting (WW) based on two multi-institutional pooled analyses (Abstract 995). J Urol 1996; 155 (Suppl 5): 559A.
165. Litwin MS, Hays RD, Fink A, et al. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA 1995; 273: 129-35.
166. Wasson JH, Cushman CC, Bruskewitz RC, Littenberg B, Mulley AG, Jr, Wennberg JE. A structured literature review of treatment for localized prostate cancer. Prostate Disease Patient Outcome Research Team. Arch Fam Med 1993; 2: 487-93.
167. Fowler FJ, Jr, Barry MJ, Lu-Yao G, Roman A, Wasson J, Wennberg JE. Patient-reported complications and follow-up treatment after radical prostatectomy. The National Medicare Experience: 1988-1990 (updated June 1993). Urology 1993; 42: 622-9.
168. Davidson PJT, van den Ouden D, Schröder FH. Radical prostatectomy: Prospective assessment of mortality and morbidity. Eur Urol 1996; 29: 168-73.
169. Walsh PC, Partin AW, Epstein JI. Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol 1994; 152: 1831-6.
170. Bagshaw MA, Cox RS, Ray GR. Status of radiation treatment of prostate cancer at Stanford University. NCI Monogr 1988; 47-60.
171. Aus G, Hermansson CG, Hugosson J, Pedersen KV. Transrectal ultrasound examination of the prostate: Complications and acceptance by patients. Br J Urol 1993; 71: 457-9.
172. Clements R, Aideyan OU, Griffiths GJ, Peeling WB. Side effects and patient acceptability of transrectal biopsy of the prostate. Clin Radiol 1993; 47: 125-6.
173. Rietbergen JBW, Boeken Kruger AE, Kranse R, Schröder FH. Complications of transrectal ultrasound-guided systematic sextant biopsies of the prostate: Evaluation of complication rates and risk factors within a population-based screening program. Urology 1997; 49: 875-80.
174. Nijs HGT, Todoir DM, Schuurman JH, Kirkels WJ, Schröder FH. Randomised trial of prostate cancer screening in the Netherlands: assessment of acceptance and motives for attendance. J Med Screen 1997; 4: 102-6.
175. Fowler FJ, Jr, Barry MJ, Lu-Yao G, Wasson J, Roman A, Wennberg J. Effect of radical prostatectomy for prostate cancer on patient quality of life: results from a Medicare survey. Urology 1995; 45: 1007-13; discussion 1013-1015.
176. Polednak AP. Trends in prostate carcinoma incidence in Connecticut (1988-1994) by age and race. Cancer 1997; 79: 99-103.
177. Stephenson RA, Smart CR, Mineau GR, James BC, Janerich DT, Dibble RL. The fall in incidence of prostate carcinoma. Cancer 1996; 77: 1342-8.
178. Hoeksema MJ, Law C. Cancer mortality rates fall: A turning point for the nation. J Natl Cancer Inst 1996; 88: 1706-7.
179. Auvinen A, Rietbergen JBW, Denis LJ, Schröder FH, Prorok PC. Prospective evaluation plan for randomised trials of prostate cancer screening. The International Prostate Cancer Screening Trial Evaluation Group. J Med Screen 1996; 3: 97-104.